TKT gives up on Replagal
Executive Summary
Transkaryotic Therapies withdraws BLA for Replagal in Fabry disease after FDA indicates that a comparison trial against Genzyme's Fabrazyme would be a prerequisite for approval. TKT submitted a special protocol assessment to the agency in November to open a discussion about a potential regulatory pathway (1"The Pink Sheet" Nov. 10, 2003, p. 17). Replagal and Fabrazyme were on near-identical development tracks for orphan drug approval; FDA cleared Genzyme's product in April (2"The Pink Sheet" April 28, 2003, p. 3)...